SCHEMBL29601760

SCHEMBL29601760

Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 2/20 0.73
ADORA3 P0DMS8 4/20 0.62
PI4KA P42356 2/20 0.62
PI4K2B Q8TCG2 2/20 0.62
PI4K2A Q9BTU6 2/20 0.62
PI4KB Q9UBF8 2/20 0.62
DPP4 P27487 1/20 0.62
MEN1 O00255 1/20 0.62
SLC28A1 O00337 1/20 0.62
MAP3K7 O43318 1/20 0.62
SLC28A2 O43868 1/20 0.62
GAPDH P04406 1/20 0.62
MAPK1 P28482 1/20 0.62
ADORA2B P29275 1/20 0.62
ADORA1 P30542 1/20 0.62
STAT6 P42226 1/20 0.62
KMT2A Q03164 1/20 0.62
SMN1; SMN2 Q16637 1/20 0.62
DOT1L Q8TEK3 1/20 0.62
SLC29A1 Q99808 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5549330 1.00 ADORA2A (0.73) ADORA2AADORA3PI4KAPI4K2BPI4K2A
SCHEMBL5936728 1.00 ADORA2A (0.73) ADORA2AADORA3PI4KAPI4K2BPI4K2A
Phosphoric Acid SCHEMBL21465094 0.94 ADORA2A (0.67) ADORA2AADORA3PI4KAPI4K2BPI4K2A
SCHEMBL14429174 0.92 ADORA3 (0.68) ADORA2AADORA3PI4KAPI4K2BPI4K2A
SCHEMBL4845625 0.89 ADORA2A (0.76) ADORA2AADORA3PI4KAPI4K2BPI4K2A
SCHEMBL546108 0.89 ADORA2A (0.76) ADORA2AADORA3PI4KAPI4K2BPI4K2A
SCHEMBL17117141 0.88 ADORA2A (0.78) ADORA2AADORA3PI4KAPI4K2BPI4K2A
SCHEMBL465644 0.88 ADORA2A (0.78) ADORA2AADORA3PI4KAPI4K2BPI4K2A
SCHEMBL13929067 0.88 ADORA2A (0.78) ADORA2AADORA3PI4KAPI4K2BPI4K2A
SCHEMBL19229274 0.88 ADORA2A (0.71) ADORA2AADORA3PI4KAPI4K2BPI4K2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12582609-B2 Cancer vaccines MODERNATX, INC. (US) 2026-03-24 US disclosed
EP-4709417-A2 POLYNUCLEOTIDES ENCODING NOROVIRUS VP1 ANTIGENS AND USES THEREOF Merck Sharp & Dohme LLC (US) 2026-03-18 EP disclosed
EP-4689071-A2 MRNA THERAPEUTICS FOR OOCYTE MATURATION Eastern Virginia Medical School (US) 2026-02-11 EP disclosed
EP-4608440-A1 RNA MOLECULES ENCODING RSV-F AND VACCINES CONTAINING THEM Pfizer Inc. (US) 2025-09-03 EP disclosed
EP-4598946-A1 NUCLEIC ACID MOLECULES ENCODING TRIF AND ADDITIONALPOLYPEPTIDES AND THEIR USE IN TREATING CANCER Flagship Pioneering Innovations V, Inc. (US) 2025-08-13 EP disclosed
US-12377136-B2 Polynucleotides encoding porphobilinogen deaminase for the treatment of acute intermittent porphyria MODERNATX, INC. (US) 2025-08-05 US disclosed
WO-2025126071-A1 RNA MOLECULES PFIZER INC. (US) 2025-06-19 WO disclosed
EP-4569112-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING AT ALTERNATIVE SPLICE SITES Remix Therapeutics Inc. (US) 2025-06-18 EP disclosed
US-20250135010-A1 CONCATEMERIC PEPTIDE EPITOPE RNAS MODERNATX, INC. (US) 2025-05-01 US disclosed
US-20250122494-A1 METHODS FOR SEPARATING MOLECULAR SPECIES OF GUANINE-RICH OLIGONUCLEOTIDES AMGEN INC. (US) 2025-04-17 US disclosed
CN-115837014-A Polynucleotides encoding relaxin 摩登纳特斯有限公司 2023-03-24 CN disclosed
WO-2023044346-A2 VACCINES FOR CORONAVIRUS PREVENTION AND TREATMENT AUSPER BIOPHARMA CO., LTD. (CN) 2023-03-23 WO disclosed
WO-2023042099-A2 VACCINES FOR CORONAVIRUS PREVENTION AND TREATMENT AUSPER BIOPHARMA CO., LTD. (CN) 2023-03-23 WO disclosed
WO-2023021421-A1 LOW-DOSE LYOPHILIZED RNA VACCINES AND METHODS FOR PREPARING AND USING THE SAME GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2023-02-23 WO disclosed
WO-2023021427-A1 FREEZE-DRYING OF LIPID NANOPARTICLES (LNPS) ENCAPSULATING RNA AND FORMULATIONS THEREOF GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2023-02-23 WO disclosed
US-20220325287-A1 THANOTRANSMISSION POLYPEPTIDES AND THEIR USE IN TREATING CANCER FLAGSHIP PIONEERING INNOVATIONS V, INC. 2022-10-13 US disclosed
WO-2022212784-A1 THANOTRANSMISSION POLYPEPTIDES AND THEIR USE IN TREATING CANCER FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) 2022-10-06 WO disclosed
WO-2022187698-A1 VLP ENTEROVIRAL VACCINES MODERNATX, INC. (US) 2022-09-09 WO disclosed
CN-109640962-B Polynucleotides encoding relaxin 摩登纳特斯有限公司 2022-07-19 CN disclosed
US-20220152178-A1 CONCATEMERIC PEPTIDE EPITOPE RNAS MODERNATX, INC. (US) 2022-05-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12377136-B2 Polynucleotides encoding porphobilinogen deaminase for the treatment of acute intermittent porphyria HMBS, ALAD, LNPEP ADORA2A 1215/4885ADORA3 1844/4885PI4KA 2080/4885
US-12582609-B2 Cancer vaccines RNMT, MICA, NSUN2 ADORA2A 4471/4885ADORA3 4110/4885PI4KA 2890/4885
US-20220325287-A1 THANOTRANSMISSION POLYPEPTIDES AND THEIR USE IN TREATING CANCER AREG, STING1, TRDMT1 ADORA2A 888/4885ADORA3 980/4885PI4KA 4114/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.